As a result of the partnership, clinicians using Epic will be able to order Foundation Medicine's genomic profiling tests directly from the EHR and view results in the system, providing them with clinical decision support.
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.
The company announced Wednesday the FDA approval of its liquid biopsy test, the second to win an agency nod in less than a month, saying it would launch the product on Friday. The FDA acquired the first ever liquid biopsy companion diagnostic, Guardant Health's Guardant360 CDx, on Aug. 10.
Although they've seen growth in the last few years, full implementation of outcome-based contracts faces hurdles like expensive technology, outmoded infrastructure and regulations that get in the way.
The company filed for FDA approval of the FoundationOne Liquid test at the end of December. Data from a clinical trial presented at an October conference showed the test had a strong ability to detect a genetic driver mutation in lung cancer.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
In the panel "The Data Problem in Scaling Artificial Intelligence in Healthcare" at the recent MedCity CONVERGE conference, experts from big pharma and health tech discussed challenges in scaling AI such as data gaps and navigating the potential ethical pitfalls of democratizing data.
In a panel discussion at the MedCity CONVERGE conference exploring the opportunities and challenges posed by the data underpinning AI tools, panelists representing big pharma, health tech and clinical data network shared some of their insights.
Data published in JAMA on lung cancer patients treated with immunotherapy drugs, gleaned from EHRs and genomic sequencing, backs up clinical trial data and validates clinico-genomic database, the companies said.
The contract, to provide comprehensive genomic sequencing to VA cancer patients, affords significant opportunities to conduct clinical research, a company executive said.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
With the approval of Loxo's Vitrakvi, pan-cancer drugs and an emphasis on real-world data are likely to become important trends trends this year.
Merck and Palantir Technologies are forming a joint research venture called Syntropy as a way to offer data analytics tools to healthcare organizations.
Prostate cancer survivor Bryce Olson says genomic sequencing shows the way forward in cancer treatment, rather than the one-size-fits-all approach.
The partnership will also enable Foundation Medicine to move into ex-US markets like Japan, where it is working with drugmaker Chugai.
Chief Commercial Officer Tom Civik said he sees reimbursement of its NGS test as opening the door for liquid biopsy reimbursement as well.